# PDL BIOPHARMA, INC.

PDL BIOPHARMA, INC. is a company headquartered in Reno, NV, United States.

## Company overview

- **Legal name:** PDL BIOPHARMA, INC.
- **Former names in filing history:** PROTEIN DESIGN LABS INC/DE (1994-02-14 to 2006-01-19)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Reno, NV, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000882104

## About

PDL BIOPHARMA, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000882104, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2020-03-11, it reported annual revenue of USD 54,757,000; net income of USD -70,411,000; total assets of USD 716,119,000 for the fiscal period ended 2019-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $54.8M (USD 54,757,000)
- **Net income:** -$70.4M (USD -70,411,000)
- **Total assets:** $716.1M (USD 716,119,000)
- **Cash and equivalents:** $193.5M (USD 193,451,000)
- **Operating cash flow:** -$32.4M (USD -32,443,000)
- **Later filings:** Revenue, Total assets, Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2018 (period ended 2018-12-31)

- **Revenue:** $198.1M (USD 198,110,000)
- **Net income:** -$68.9M (USD -68,859,000)
- **Total assets:** $963.7M (USD 963,736,000)
- **Cash and equivalents:** $394.6M (USD 394,590,000)
- **Operating cash flow:** -$13.4M (USD -13,425,000)
- **Later filings:** Revenue, Total assets, Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2017 (period ended 2017-12-31)

- **Revenue:** $320.1M (USD 320,060,000)
- **Net income:** $110.7M (USD 110,748,000)
- **Total assets:** $1.2B (USD 1,243,123,000)
- **Cash and equivalents:** $527.3M (USD 527,266,000)
- **Operating cash flow:** $40.6M (USD 40,624,000)
- **Later filings:** Revenue: shown as originally filed; later filings report different values for the same periods.

### FY2016 (period ended 2016-12-31)

- **Revenue:** $244.3M (USD 244,301,000)
- **Net income:** $63.6M (USD 63,606,000)
- **Total assets:** $1.2B (USD 1,215,387,000)
- **Cash and equivalents:** $147.2M (USD 147,154,000)
- **Operating cash flow:** $101.7M (USD 101,718,000)

## Recent SEC filings

- Form 10-K — filed 2021-03-29 — period 2020-12-31 — 10-K
- Form SC 13D — filed 2021-01-11
- Form SC 13G — filed 2020-12-16
- Form 8-K — filed 2020-12-14 — period 2020-12-11 — 8-K
- Form 8-K — filed 2020-12-08 — period 2020-12-04 — 8-K
- Form 10-Q — filed 2020-11-13 — period 2020-09-30 — 10-Q
- Form 8-K — filed 2020-11-13 — period 2020-11-11 — 8-K
- Form 8-K — filed 2020-10-07 — period 2020-10-01 — 8-K
- Form 8-K — filed 2020-10-02 — period 2020-09-30 — 8-K
- Form 8-K — filed 2020-09-10 — period 2020-09-10 — 8-K
- Form 8-K — filed 2020-09-10 — period 2020-09-10 — 8-K
- Form 8-K — filed 2020-09-09 — period 2020-09-09 — 8-K

---

Updated: 2026-10-23T20:13:49Z

Canonical page: https://altss.com/profile/pdl-biopharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology